Q2 2026 13F filing
Updated 30 days ago86 disclosed positions worth $189.2M
Full holdings
Every line item disclosed in Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | G GOOGN Alphabet Inc-Cl C | $32.2M | 91.2K | 17.03% | — |
| 2 | A APOS Apollo Global Management, Inc. | $26.6M | 225.0K | 14.07% | — |
| 3 | S SNDX Syndax Pharmaceutical, Inc. | $9.6M | 437.2K | 5.05% | — |
| 4 | X XERS Xeris Biopharma Holdings, Inc. | $8.4M | 1.06M | 4.44% | — |
| 5 | T TVTX Travere Therapeutics, Inc. | $8.4M | 147.3K | 4.42% | — |
| 6 | P PB Protagonist Therapeutics, Inc | $7.7M | 63.0K | 4.08% | — |
| 7 | B BBIO Bridgebio Pharma, Inc. | $6.9M | 92.8K | 3.66% | — |
| 8 | J JPM-PM Iovance Biotherapeutics, Inc. | $6.7M | 1.60M | 3.52% | — |
| 9 | A ALKS Alkermes PLC | $6.4M | 121.8K | 3.37% | — |
| 10 | J JPM-PM JPMorgan Chase & Co. | $5.9M | 18.1K | 3.13% | — |
| 11 | N NOC Janus Henderson AAA CLO ETF | $4.7M | 93.5K | 2.50% | — |
| 12 | L LPLA LPL Financial Holdings Inc. | $4.6M | 16.5K | 2.46% | — |
| 13 | C COGT Cogent Biosciences Inc. | $4.3M | 111.1K | 2.27% | — |
| 14 | T TGTX TG Therapeutics, Inc. | $3.7M | 66.8K | 1.94% | — |
| 15 | ? N/A Catalyst Pharmaceuticals, Inc. | $3.6M | 114.0K | 1.89% | — |
| 16 | M MGRB Agios Pharmaceutical, Inc. | $3.5M | 95.1K | 1.86% | — |
| 17 | V VRDN Viridian Therapeutics, Inc. | $3.3M | 181.0K | 1.76% | — |
| 18 | R RLMD Relmada Therapeutics, Inc. | $3.1M | 451.0K | 1.65% | — |
| 19 | R RCUS Arcus Biosciences, Inc. | $2.5M | 81.2K | 1.32% | — |
| 20 | H HELP Cybin Inc | $2.4M | 370.0K | 1.29% | — |
| 21 | S STT-PG SPDR S&P Biotech ETF | $2.4M | 15.0K | 1.25% | — |
| 22 | R RZLT Rezolute, Inc. | $1.9M | 370.0K | 1.02% | — |
| 23 | A AB AllianceBernstein Holding L.P. | $1.7M | 48.0K | 0.89% | — |
| 24 | M MDGL Madrigal Pharmaaceuticals, Inc. | $1.6M | 3.0K | 0.85% | — |
| 25 | A ATRC AtriCure, Inc. | $1.4M | 51.4K | 0.76% | — |
| 26 | D DCGO DocGo, Inc. | $1.4M | 2.67M | 0.73% | — |
| 27 | A ARDX Ardelyx, Inc. | $1.3M | 263.2K | 0.71% | — |
| 28 | R RARE Ultragenyx Pharmaceutical Inc. | $1.3M | 38.1K | 0.67% | — |
| 29 | C CVX The Panagram BBB-B CLO ETF | $1.3M | 47.8K | 0.67% | — |
| 30 | C CGEM Cullinan Therapeutics, Inc. | $1.3M | 69.2K | 0.67% | — |
| 31 | V VERA Vera Therapeutics, Inc. | $1.1M | 26.0K | 0.59% | — |
| 32 | O OBIO Orchestra Biomed Holdings, Inc. | $1.1M | 253.7K | 0.58% | — |
| 33 | S SPRB Spruce Biosciences, Inc. | $1.1M | 20.0K | 0.57% | — |
| 34 | C CNTB Connect Biopharma Holdings Limited | $1.1M | 444.9K | 0.56% | — |
| 35 | E ETHA iShares Biotechnology ETF | $1M | 5.5K | 0.55% | — |
| 36 | J JNJ Johnson & Johnson | $1M | 4.0K | 0.54% | — |
| 37 | B BIIB Biogen Inc. | $864K | 4.0K | 0.46% | — |
| 38 | P PFE Pfizer Inc. | $779K | 32.3K | 0.41% | — |
| 39 | A AAPL Apple Inc. | $722K | 2.5K | 0.38% | — |
| 40 | C CNQ Canadian Natural Resources Limited | $664K | 16.8K | 0.35% | — |
| 41 | P PTHS Pelthos Therapeutics, Inc. | $624K | 22.1K | 0.33% | — |
| 42 | I IBM International Business Machines | $602K | 2.1K | 0.32% | — |
| 43 | M MSFT Microsoft Corporation | $597K | 1.6K | 0.32% | — |
| 44 | V VSTM Verastem Inc. | $592K | 155.0K | 0.31% | — |
| 45 | K KURA Kura Oncology, Inc. | $579K | 52.8K | 0.31% | — |
| 46 | S SLDB Solid Bioscience Inc. | $562K | 56.2K | 0.30% | — |
| 47 | D DD DuPont de Nemours, Inc. | $511K | 3.8K | 0.27% | — |
| 48 | I INSM Insmed Incorporated | $453K | 4.3K | 0.24% | — |
| 49 | L LBRX LB Pharmaceuticals, Inc. | $421K | 13.0K | 0.22% | — |
| 50 | C CDNA CareDx, Inc. | $388K | 13.6K | 0.21% | — |